Recurrent venous thromboembolism under anticoagulant therapy: A high risk in adenocarcinoma?

Renaud Descourt; Grégoire Le Gal; Francis Couturaud; Dominique Mottier; Luc Bressollette; Gilles Robinet; Christophe Rogé; Emmanuel Oger; Christophe Leroyer

doi:10.1160/TH06-01-0009

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(05): 912-913
DOI: 10.1160/TH06-01-0009

Letters to the Editor

Schattauer GmbH

Recurrent venous thromboembolism under anticoagulant therapy: A high risk in adenocarcinoma?

Authors

Renaud Descourt

¹Département de Médecine Interne et Pneumologie, EA 38 78, Hôpital de la Cavale Blanche, Brest, France
Grégoire Le Gal

¹Département de Médecine Interne et Pneumologie, EA 38 78, Hôpital de la Cavale Blanche, Brest, France
Francis Couturaud

¹Département de Médecine Interne et Pneumologie, EA 38 78, Hôpital de la Cavale Blanche, Brest, France
Dominique Mottier

¹Département de Médecine Interne et Pneumologie, EA 38 78, Hôpital de la Cavale Blanche, Brest, France
Luc Bressollette

¹Département de Médecine Interne et Pneumologie, EA 38 78, Hôpital de la Cavale Blanche, Brest, France
Gilles Robinet

¹Département de Médecine Interne et Pneumologie, EA 38 78, Hôpital de la Cavale Blanche, Brest, France
Christophe Rogé

²Service de pneumologie, CH de Morlaix, Morlaix, France
Emmanuel Oger

¹Département de Médecine Interne et Pneumologie, EA 38 78, Hôpital de la Cavale Blanche, Brest, France
Christophe Leroyer

¹Département de Médecine Interne et Pneumologie, EA 38 78, Hôpital de la Cavale Blanche, Brest, France

Abstract

Full Text

References

References
1 Heit JA, O’Fallon WM, Petterson TM. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-8.
2 Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107 Suppl: (Suppl. 01) I17-I21.
3 Blom JW, Doggen CJ, Osanto S. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
4 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 Suppl: (Suppl. 03) 338S-400S.
5 Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004; 02: 1760-5.
6 Lee A, Levine M. Treatment of venous thromboembolism in cancer patients. Cancer Control 2005; 12 Suppl: (Suppl. 01) 17-21.
7 Lee AY, Levine MN, Baker RI. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
8 Lacut K, Oger E, Le Gal G. et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 2004; 18: 477-82.
9 Linkins LA, Stretton R, Probyn L. et al. Interobserver agreement on ultrasound measurements of residual vein diameter, thrombus echogenicity and Doppler venous flow in patients with previous venous thrombosis. Thromb Res 2006; 117: 241-7.
10 Trousseau A. Phlegmatia alba dolens. Clinique médicale de l’Hôtel Dieu. Paris: 1861
11 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-9.
12 Wahrenbrock M, Borsig L, Le D. et al. Selectinmucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003; 112: 853-62.